To read more on this topic click here.
Inhalable drug given green light
News
Author: Simge Eva DoganPublished: 9 January 2019
Prep:
Cook:
Serves:
The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.
INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.
Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.
“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”
For more information on Parkinson’s medication please visit the EPDA website.
Read more:
Researchers create Parkinson’s-resistant stem cells
Memory loss could be an indication of Parkinson’s
Last Month
Next Month
Share this story
Related articles
In my country
“Many patients still receive the Parkinson’s diagnosis late”
We hear from the president of Društvo Trepetlika
READ MORE
Recipes & Nutrition
Timbale of pasta with tomato and shrimps
Recipe: seafood timbale with cheese, tomato and pasta
READ MORE
PD in Practice
How does facial masking affect people with Parkinson’s?
Find out what causes hypomimia – and how the symptom can be treated
READ MORE
Comments